Daily pill cuts body weight by up to 13% after 3 months in ... - NBC News
Sep 10, 2024 · The rate of weight loss with the experimental pill, called amycretin, appears to be more rapid than what’s seen for other drugs.
Weight loss: Amycretin pill may be more effective than semaglutide
Sep 12, 2024 · Amycretin is a new drug developed by Novo Nordisk that mimics GLP-1 and amylin hormones to suppress appetite and reduce body weight. In a phase 1 trial, it showed a 13% weight loss over 3 months,...
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting …
Sep 11, 2024 · Novo Nordisk presented data from a phase 1 trial of its dual-acting oral drug, amycretin, that targets amylin and GLP-1 receptors. The drug showed 13.1% weight loss after 12 weeks, but also high...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
'Remarkable' Weight Loss With Novel Oral Combo in Phase 1
Sep 12, 2024 · MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to phase 1, first-in-human study data presented...
Novo Nordisk weight loss pill may be more effective than Wegovy …
Sep 10, 2024 · In a small Phase 1 trial, a 50-mg dose of the daily pill called amycretin, which activates receptors of both the amylin and GLP-1 hormones, led to 10.4% weight loss at about three months after...
Novo Nordisk experimental obesity pill has mild-to-moderate side ...
Sep 10, 2024 · Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.
Ozempic Maker Teases New Weight Loss Pill Amycretin - Forbes
Mar 7, 2024 · At an investor event on Thursday, Novo Nordisk shared data from an early stage clinical trial of an experimental weight loss drug called amycretin, an oral treatment that trial results suggest...
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
3 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
New Ozempic-like pill reduces weight by 13%, study finds
Amycretin is a pill that acts like two hormones involved in weight loss, amylin and GLP-1, and could rival Ozempic. In a 12-week trial, it helped people lose 13.1 per cent of their body weight on average.